pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag.
2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.
Additional notes:
Alpha-synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Cat. #:
152046
Research Fields:
Neurobiology
Target:
Alpha-synuclein
Application notes:
pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag.
2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.
References:
El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
